On Tuesday, Following U.S. Stocks were among the “Top Gainers”:Synthetic Biologics, (NYSEMKT:SYN), ACADIA Pharmaceuticals, (NASDAQ:ACAD), Bridge Capital Holdings, (NASDAQ:BBNK), Geron Corporation, (NASDAQ:GERN)

• Synthetic Biologics, (NYSEMKT:SYN), with shares inclined 18.07%, closed at $2.94.

• ACADIA Pharmaceuticals, (NASDAQ:ACAD), with shares jumped 17.85%, settled at $45.88, hitting new 52-week high of $46.48.

• Bridge Capital Holdings, (NASDAQ:BBNK), with shares climbed 13.91%, and closed at $25.39, hitting new 52-week high of $25.40.

• Geron Corporation, (NASDAQ:GERN), surged 12.02%, and closed at $4.10, hitting new 52-week high of $4.32.

Latest NEWS regarding these Stocks are depicted underneath:

Synthetic Biologics Inc. (NYSEMKT:SYN):

Synthetic Biologics Inc. (SYN), a developer of pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome, declared that the Corporation intends to release its financial results for the year ended December 31, 2014 on Monday, March 16, 2015. The Corporation will also hold an investor conference call on Monday, March 16th, at 8:30 a.m. EDT.

During the call, Jeffrey Riley, Synthetic Biologics’ Chief Executive Officer, will provide an update on the Corporation’s C. difficile prevention, constipation-predominant irritable bowel syndrome (C-IBS), Pertussis (whooping cough) and multiple sclerosis (MS) programs. C. Evan Ballantyne, Synthetic Biologics’ Chief Financial Officer, will review the Corporation’s financial results for the year ended December 31, 2014.

Synthetic Biologics, Inc. is a biotechnology corporation. The Corporation focused on the development of anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases. It is developing an oral biologic to protect the gastrointestinal microflora from the effects of IV antibiotics for the prevention of C.

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)

Formerly on February 26, ACADIA Pharmaceuticals Inc. (ACAD), a biopharmaceutical corporation focused on the development and commercialization of innovative medicines that address unmet medical needs in neurological and related central nervous system disorders, declared its financial results for the fourth quarter and year ended December 31, 2014.

ACADIA stated a net loss of $28.4 million, or $0.28 per ordinary share, for the fourth quarter of 2014, contrast to a net loss of $12.0 million, or $0.13 per ordinary share, for the fourth quarter of 2013. The net losses for the fourth quarters of 2014 and 2013 comprised of $4.6 million and $2.2 million, respectively, in non-cash, stock-based compensation expense. For the year ended December 31, 2014, ACADIA stated a net loss of $92.5 million, or $0.95 per ordinary share, contrast to a net loss of $37.9 million, or $0.44 per ordinary share, for 2013. The net losses for 2014 and 2013 comprised of $16.0 million and $5.7 million, respectively, in non-cash, stock-based compensation expense.

At December 31, 2014, ACADIA’s cash, cash equivalents, and investment securities totaled $322.5 million contrast to $185.8 million at December 31, 2013. This raise was primarily due to net proceeds from sales of equity securities, counting $196.8 million raised in a public offering in March 2014, offset in part by cash used to fund ACADIA’s operations.

Research and development expenses raised to $18.2 million for the fourth quarter of 2014, counting $1.7 million in stock-based compensation, from $7.9 million for the comparable quarter of 2013, counting $791,000 in stock-based compensation. This raise was primarily due to an raise of $7.8 million in external service costs associated with the development of pimavanserin. Raises in costs associated with ACADIA’s expanded research and development organization, counting $1.5 million in raised personnel costs and $948,000 in raised stock-based compensation expense, also contributed to the quarter-over-quarter rise.

General and administrative expenses raised to $10.4 million for the fourth quarter of 2014, counting $2.9 million in stock-based compensation, from $4.3 million for the comparable quarter of 2013, counting $1.4 million in stock-based compensation. This raise was due to a $2.1 million raise in external service costs largely related to ACADIA’s commercial preparations for the planned launch of NUPLAZID. Also contributing to the quarter-over-quarter raise in general and administrative expenses was a $1.7 million raise in personnel expenses largely related to ACADIA’s preparations for the planned launch of NUPLAZID, in addition to a $1.5 million raise in stock-based compensation expense.

ACADIA anticipates that the level of cash used in its operations will raise in future periods in order to fund its work related to the New Drug Application (NDA) submission and review and commercial activities for NUPLAZID, and its ongoing and planned development activities for pimavanserin for other indications. ACADIA presently anticipates that its cash, cash equivalents, and investment securities will be sufficient to fund its planned operations at least into the second half of 2016.

ACADIA is a biopharmaceutical corporation focused on the development and commercialization of innovative medicines to address unmet medical needs in neurological and related central nervous system disorders.

Bridge Capital Holdings (NASDAQ:BBNK)

Western Alliance Bancorporation (WAL) and Bridge Capital Holdings (BBNK), declared that they have signed a definitive contract following which Western Alliance Bancorporation will attain Bridge Capital Holdings. Right away following the completion of the attainment, Bridge Capital’s principal operating partner, Bridge Bank, will merge with and into Western Alliance Bank, a wholly owned partner of Western Alliance Bancorporation. Following the bank merger, Western Alliance plans to operate its Northern California offices and the existing Bridge Bank offices as a combined division under the Bridge Bank trade name.

The Contract provides that each shareholder of Bridge Capital Holdings will receive 0.8145 of a share of Western Alliance Bancorporation and $2.39 in cash for each share of Bridge ordinary stock owned. In aggregate, the transaction is valued at about $425 million, counting certain unvested restricted stock awards and stock options formerly issued by Bridge Capital that will be converted to Western Alliance equity awards under the terms of the Contract.

Daniel P. Myers, President and Chief Executive Officer of Bridge Capital Holdings, said, “We’re very excited at the growth opportunity this partnership with Western Alliance Bank represents for Bridge Bank. Our momentum is strong coming into this merger, and the additional resources it brings will allow us to better support our growing roster of business clients, and accelerate our expansion in all of our business lines and markets we serve.”

Western Alliance Bancorporation is a leading bank holding corporation providing comprehensive business banking and related financial services through its wholly owned banking partner, Western Alliance Bank.

Bridge Bank is a full-service professional business bank founded in the highly competitive climate of Silicon Valley in 2001. From the very startning, its aim has been to offer small-market and middle-market businesses from across many industries a better way to bank.

Geron Corporation (NASDAQ:GERN)

Formerly on March 3, Geron Corporation (GERN) stated financial results for the fourth quarter and year ended December 31, 2014 and recent events.

Fourth Quarter 2014 Results:

Net loss for the fourth quarter of 2014 was $8.9 million, or $0.06 per share, contrast to $9.3 million, or $0.07 per share, for the comparable 2013 period. Proceeds for the fourth quarter of 2014 were $178,000 contrast to $225,000 for the comparable 2013 period. The corporation ended 2014 with $170.6 million in cash and investments, which comprised of receipt of an upfront payment of $35.0 million for the license rights granted by the corporation to Janssen Biotech, Inc. (“Janssen”) under the exclusive partnership and license contract (the “Partnership Contract”) reached between the parties in November 2014, which has been recorded as deferred proceed as of December 31, 2014.

Total operating expenses for the fourth quarter of 2014 were $9.2 million contrast to $9.5 million for the comparable 2013 period. Research and development expenses for the fourth quarter of 2014 were $4.4 million contrast to $5.1 million for the comparable 2013 period. General and administrative expenses for the fourth quarter of 2014 were $4.8 million contrast to $4.0 million for the comparable 2013 period. Operating expenses for the 2013 fourth quarter also comprised of restructuring charges of $430,000 in connection with the corporation`s decisions to discontinue its discovery research programs and close its research laboratory facility in 2013.

Year-End 2014 Results:

Net loss for 2014 was $35.7 million, or $0.23 per share, contrast to $38.4 million, or $0.30 per share, for 2013. License fee and royalty proceeds for 2014 and 2013 were $1.2 million and $1.3 million, respectively.

Total operating expenses for 2014 were $37.5 million contrast to $40.2 million for 2013. Research and development expenses for 2014 were $20.7 million contrast to $23.2 million for 2013. General and administrative expenses for 2014 were $16.8 million contrast to $15.6 million for 2013. Year-to-date operating expenses for 2013 also comprised of restructuring charges of $1.5 million.

Geron is a clinical stage biopharmaceutical corporation focused on the development of a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies.

DISCLAIMER:

This article is published by www.wsnewspublishers.com. The Content described in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.

All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.

Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.

Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.